SCHEMBL19954923

SCHEMBL19954923

CC(C)c1ccc2sc(CC(C)c3ccc4ncsc4c3)nc2c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.40
SCN4A P35499 1/20 0.40
RAB9A P51151 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
HDAC6 Q9UBN7 1/20 0.38
PFKFB3 Q16875 6/20 0.36
NTRK1 P04629 1/20 0.35
NTRK2 Q16620 1/20 0.35
FFAR1 O14842 1/20 0.34
DYRK1A Q13627 2/20 0.34
ALDH1A1 P00352 1/20 0.34
PKM P14618 1/20 0.34
TGFBR1 P36897 2/20 0.34
AKR1B1 P15121 2/20 0.34
OGA O60502 2/20 0.34
CLK1 P49759 1/20 0.33
CLK2 P49760 1/20 0.33
CLK3 P49761 1/20 0.33
GSK3B P49841 1/20 0.33
CLK4 Q9HAZ1 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19308856 0.93 NPC1 (0.48) NPC1SCN4ARAB9ASMN1; SMN2PFKFB3
SCHEMBL24840305 0.89 SMN1; SMN2 (0.39) NPC1RAB9ASMN1; SMN2PFKFB3NTRK1
SCHEMBL20004008 0.83 RAB9A (0.47) NPC1SCN4ARAB9ASMN1; SMN2PFKFB3
SCHEMBL26342576 0.81 OGA (0.36) NPC1SCN4ARAB9ASMN1; SMN2HDAC6
SCHEMBL277372 0.79 NPC1 (0.50) NPC1SCN4ARAB9ASMN1; SMN2PFKFB3
SCHEMBL21871342 0.78 RAB9A (0.43) NPC1RAB9ASMN1; SMN2NTRK1NTRK2
SCHEMBL18898373 0.78 HDAC6 (0.37) NPC1SCN4ARAB9ASMN1; SMN2HDAC6
SCHEMBL19966718 0.77 RAB9A (0.49) NPC1SCN4ARAB9ASMN1; SMN2HDAC6
SCHEMBL24420726 0.76 SMN1; SMN2 (0.51) NPC1SCN4ARAB9ASMN1; SMN2ALDH1A1
SCHEMBL19966707 0.76 SMN1; SMN2 (0.51) NPC1SCN4ARAB9ASMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230382907-A1 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES ENLIVEN INC. 2023-11-30 US disclosed
US-11241450-B2 Uridine diphosphate derivatives, prodrugs, compositions and uses thereof TUFTS UNIVERSITY (US) 2022-02-08 US disclosed
WO-2021194959-A1 TREATMENT OF EYE DISORDERS WITH URIDINE PHOSPHATE DERIVATIVES GLIAGUARD, INC. (US) 2021-09-30 WO disclosed
US-11124536-B2 Uridine nucleoside derivatives, compositions and methods of use TUFTS UNIVERSITY (US) 2021-09-21 US disclosed
US-11072627-B2 Uridine diphosphate derivatives, compositions and methods for treating neurodegenerative disorders TUFTS UNIVERSITY (US) 2021-07-27 US disclosed
US-20210069226-A1 URIDINE DIPHOSPHATE DERIVATIVES, PRODRUGS, COMPOSITIONS AND USES THEREOF TUFTS UNIVERSITY (US) 2021-03-11 US disclosed
US-20200399302-A1 URIDINE NUCLEOSIDE DERIVATIVES, COMPOSITIONS AND METHODS OF USE TUFTS UNIVERSITY 2020-12-24 US disclosed
US-20190309009-A1 URIDINE DIPHOSPHATE DERIVATIVES, COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISORDERS TUFTS UNIVERSITY 2019-10-10 US disclosed
US-10392377-B2 Substituted 2-imino-1,3-thiazolidin-4-ones as N-arachidonoylethanolamine cellular uptake inhibitors UNIVERSITAT BERN (CH) 2019-08-27 US disclosed
US-20190119265-A1 THIAZOLIDINONE COMPOUNDS AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL DISORDERS AND INFLAMMATION, IN PARTICULAR NEUROINFLAMMATION UNIVERSITAT BERN (CH) 2019-04-25 US disclosed
US-20180085386-A1 URIDINE MONOPHOSPHATE AND TRIPHOSPHATE DERIVATIVES, COMPOSITIONS AND METHODS OF USE TUFTS UNIVERSITY 2018-03-29 US disclosed
US-9913855-B2 Uridine diphosphate derivatives, prodrugs, compositions and uses thereof TUFTS UNIVERSITY (US) 2018-03-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11124536-B2 Uridine nucleoside derivatives, compositions and methods of use P2RY6, UPP1, UMPS NPC1 1587/4885SCN4A 2514/4885RAB9A 1050/4885
US-20190309009-A1 URIDINE DIPHOSPHATE DERIVATIVES, COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISORDERS P2RY6, P2RX6, P2RY1 NPC1 835/4885SCN4A 2014/4885RAB9A 1234/4885
US-20200399302-A1 URIDINE NUCLEOSIDE DERIVATIVES, COMPOSITIONS AND METHODS OF USE P2RY6, UPP1, UMPS NPC1 1587/4885SCN4A 2514/4885RAB9A 1050/4885
US-20180085386-A1 URIDINE MONOPHOSPHATE AND TRIPHOSPHATE DERIVATIVES, COMPOSITIONS AND METHODS OF USE P2RY6, UPP1, UMPS NPC1 1808/4885SCN4A 2470/4885RAB9A 965/4885
US-20230382907-A1 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES ABL1, ABL2, BCR NPC1 4143/4885SCN4A 3844/4885RAB9A 1191/4885
US-10392377-B2 Substituted 2-imino-1,3-thiazolidin-4-ones as N-arachidonoylethanolamine cellular uptake inhibitors CNR2, CNR1, GPR18 NPC1 15/4885SCN4A 2611/4885RAB9A 2866/4885
US-20190119265-A1 THIAZOLIDINONE COMPOUNDS AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL DISORDERS AND INFLAMMATION, IN PARTICULAR NEUROINFLAMMATION GRIN2B, IL1B, GRIA4 NPC1 1319/4885SCN4A 1528/4885RAB9A 3087/4885
US-20210069226-A1 URIDINE DIPHOSPHATE DERIVATIVES, PRODRUGS, COMPOSITIONS AND USES THEREOF UMPS, UPP1, UGDH NPC1 1110/4885SCN4A 2734/4885RAB9A 246/4885
US-11241450-B2 Uridine diphosphate derivatives, prodrugs, compositions and uses thereof UMPS, UPP1, UGDH NPC1 1110/4885SCN4A 2734/4885RAB9A 246/4885
US-11072627-B2 Uridine diphosphate derivatives, compositions and methods for treating neurodegenerative disorders P2RY6, P2RX6, P2RY1 NPC1 584/4885SCN4A 1745/4885RAB9A 1223/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.